Nucleic Acid Therapeutics CDMO Market Analysis 2026

According to Cognitive Market Research, the global Nucleic Acid Therapeutics Market size will be USD 7962.4 million in 2025. It will expand at a compound annual growth rate (CAGR) of 14.60% from 2025 to 2033.

• North America held the major market share of 37% of the global revenue with a market size of USD 2946.09 million in 2025 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2025 to 2033.
• Europe accounted for a market share of over 29% of the global revenue with a market size of USD 2309.10 million.
• APAC held the market share of 24% of the global revenue with a market size of USD 1910.98 million in 2025 and will grow at a compound annual growth rate (CAGR) of 16.6% from 2025 to 2033.
• South America has a market share of more than 3.8% of the global revenue with a market size of USD 302.57 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.6% from 2025 to 2033.
• Middle East had a market share of around 4.00% of the global revenue and was estimated at a market size of USD 318.50 million in 2025 and will grow at a compound annual growth rate (CAGR) of 13.9% from 2025 to 2033.
• Africa had a market share of around 2.20% of the global revenue and was estimated at a market size of USD 175.17 million in 2025 and will grow at a compound annual growth rate (CAGR) of 14.3% from 2025 to 2033.
• Gene Therapies is the fastest growing segment of the Nucleic Acid Therapeutics Market industry

Introduction of the Nucleic Acid Therapeutics Market

Nucleic acid therapeutics represent a cutting-edge class of biopharmaceuticals designed to modulate gene expression by targeting specific RNA or DNA sequences. These therapies include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), gene therapies, aptamers, and mRNA-based treatments, offering highly precise interventions for genetic, oncological, and infectious diseases. Unlike traditional small molecules, nucleic acid therapeutics address the root cause of diseases at the molecular level, enabling disease modification or potential cures. The market has witnessed robust growth due to rising incidences of rare genetic disorders, increased investment in biotechnology research, and successful commercialization of therapies like Spinraza and Onpattro. Technological advancements in delivery platforms and favorable regulatory support are further propelling industry expansion. As personalized medicine gains traction and RNA-based vaccines establish new standards, the nucleic acid therapeutics market is positioned for sustained growth and innovation over the coming decade.

For instance, in March 2024, Exothera has launched a new nucleic acids service, powered by its proprietary NTensify platform. This offering aims to accelerate the development of nucleic acid-based therapies, including mRNA and gene therapies, by enhancing delivery and production capabilities. Exothera’s service is designed to support the growing demand for advanced therapeutics, providing a streamlined approach to process development and scaling for the biotech and pharmaceutical sectors. https://www.contractpharma.com/breaking-news/exothera-launches-nucleic-acids-service-offering-powered-by-ntensify/

Impact of Trump Tariffs on the Nucleic Acid Therapeutics Market

Tariffs on imported goods pose significant challenges to the nucleic acid therapeutics market by escalating production costs and disrupting global supply chains. According to a 2025 survey by the Biotechnology Innovation Organization (BIO), nearly 90% of U.S. biotech firms depend on imported components for over half of their FDA-approved products, making them vulnerable to trade policy shifts. The U.S. administration's imposition of a 10% tariff on all imported goods, along with tariffs of up to 245% on Chinese active pharmaceutical ingredients (APIs), has intensified cost pressures. As a result, pharmaceutical imports surged to over $50 billion in March 2025, as companies rushed to accelerate shipments to preempt tariff impacts.

The increased costs caused by tariffs could hinder research and development efforts in the nucleic acid therapeutics market. According to an analysis by Ernst & Young (EY), tariffs could lead to an annual increase of $51 billion in U.S. drug costs. This financial burden may force companies to scale back their R&D budgets, slowing down the development of innovative therapies. In a sector where rapid advancements are critical, this reduced funding could delay the introduction of new treatments for genetic diseases, cancer, and other conditions requiring gene-based therapies.

Moreover, the tariffs disrupt the global supply chain, delaying the availability of critical raw materials and components. The nucleic acid therapeutics sector is highly reliant on specialized materials, including APIs, which are affected by the tariffs. The disruption in supply chains may lead to delays in clinical trials and the manufacturing of therapeutics. For smaller companies with limited resources, these delays can severely impact their ability to bring new therapies to market, slowing the pace of innovation and reducing patient access to potentially life-saving treatments.

The broader macroeconomic impact of tariffs further complicates the business environment for the nucleic acid therapeutics market. The inflated production costs and the surge in drug prices could lead to reduced profitability for companies in the sector. With increased financial pressure, companies may struggle to maintain growth or expand operations, limiting their ability to meet the growing global demand for advanced therapies. Ultimately, while tariffs are designed to bolster domestic manufacturing, they inadvertently create substantial barriers for the nucleic acid therapeutics market by inflating costs and impeding the development and distribution of innovative treatments.